Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate

Dina Abdelwahab Elhamahmi, Raymond L. Heilman, Byron Smith, Janna Huskey, Hasan Khamash, Bruce Kaplan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Our aim was to determine the impact of converting from tacrolimus to belatacept in patients with stable low estimated glomerular filtration rate (eGFR) early after kidney transplant. Methods This is a single-center retrospective case control study. During this study period, we had a clinical protocol to convert patients to belatacept if they had a stable but low GFR and they were at least 1-month posttransplant. Eligible patients had stable but low eGFR usually < 40 mL/min per 1.73 m2. We used direct matching to select 1 control case for each patient converted to belatacept. The primary outcome was the change in eGFR from the point of belatacept conversion to 4 months postconversion (delta eGFR). Results There were 30 patients in the conversion group and 30 in a direct matched control group. The median preconversion eGFR for the entire cohort was 23.0 mL/min per 1.73 m2 with an interquartile range of 15.7 to 31.4. The delta eGFR was 11.0 (12.9) mL/min per 1.73 m2 in belatacept group and 4.8 (10.5) mL/min per 1.73 m2 in the control group (P = 0.045). Acute rejection postconversion occurred in 5 (16.7%) in the conversion group and none of the control group (P = 0.052). Although the delta improvement in eGFR was about 6 mL/min better in the Belatacept group, there was no difference in the slope of inverse creatinine during the 12-month period after conversion between the groups. Conclusions We conclude that early belatacept conversion in kidney transplant recipients with stable low eGFR may only result in a modest increase in GFR.

Original languageEnglish (US)
Pages (from-to)478-483
Number of pages6
JournalTransplantation
Volume102
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Glomerular Filtration Rate
Kidney
Control Groups
Transplant Recipients
Abatacept
Tacrolimus
Clinical Protocols
Case-Control Studies
Creatinine
Research Design
Transplants

ASJC Scopus subject areas

  • Transplantation

Cite this

Elhamahmi, D. A., Heilman, R. L., Smith, B., Huskey, J., Khamash, H., & Kaplan, B. (2018). Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate. Transplantation, 102(3), 478-483. https://doi.org/10.1097/TP.0000000000001985

Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate. / Elhamahmi, Dina Abdelwahab; Heilman, Raymond L.; Smith, Byron; Huskey, Janna; Khamash, Hasan; Kaplan, Bruce.

In: Transplantation, Vol. 102, No. 3, 01.03.2018, p. 478-483.

Research output: Contribution to journalArticle

Elhamahmi, DA, Heilman, RL, Smith, B, Huskey, J, Khamash, H & Kaplan, B 2018, 'Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate', Transplantation, vol. 102, no. 3, pp. 478-483. https://doi.org/10.1097/TP.0000000000001985
Elhamahmi, Dina Abdelwahab ; Heilman, Raymond L. ; Smith, Byron ; Huskey, Janna ; Khamash, Hasan ; Kaplan, Bruce. / Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate. In: Transplantation. 2018 ; Vol. 102, No. 3. pp. 478-483.
@article{40835c790106402b88ad6ba3e8c31b2a,
title = "Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate",
abstract = "Background Our aim was to determine the impact of converting from tacrolimus to belatacept in patients with stable low estimated glomerular filtration rate (eGFR) early after kidney transplant. Methods This is a single-center retrospective case control study. During this study period, we had a clinical protocol to convert patients to belatacept if they had a stable but low GFR and they were at least 1-month posttransplant. Eligible patients had stable but low eGFR usually < 40 mL/min per 1.73 m2. We used direct matching to select 1 control case for each patient converted to belatacept. The primary outcome was the change in eGFR from the point of belatacept conversion to 4 months postconversion (delta eGFR). Results There were 30 patients in the conversion group and 30 in a direct matched control group. The median preconversion eGFR for the entire cohort was 23.0 mL/min per 1.73 m2 with an interquartile range of 15.7 to 31.4. The delta eGFR was 11.0 (12.9) mL/min per 1.73 m2 in belatacept group and 4.8 (10.5) mL/min per 1.73 m2 in the control group (P = 0.045). Acute rejection postconversion occurred in 5 (16.7{\%}) in the conversion group and none of the control group (P = 0.052). Although the delta improvement in eGFR was about 6 mL/min better in the Belatacept group, there was no difference in the slope of inverse creatinine during the 12-month period after conversion between the groups. Conclusions We conclude that early belatacept conversion in kidney transplant recipients with stable low eGFR may only result in a modest increase in GFR.",
author = "Elhamahmi, {Dina Abdelwahab} and Heilman, {Raymond L.} and Byron Smith and Janna Huskey and Hasan Khamash and Bruce Kaplan",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/TP.0000000000001985",
language = "English (US)",
volume = "102",
pages = "478--483",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate

AU - Elhamahmi, Dina Abdelwahab

AU - Heilman, Raymond L.

AU - Smith, Byron

AU - Huskey, Janna

AU - Khamash, Hasan

AU - Kaplan, Bruce

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background Our aim was to determine the impact of converting from tacrolimus to belatacept in patients with stable low estimated glomerular filtration rate (eGFR) early after kidney transplant. Methods This is a single-center retrospective case control study. During this study period, we had a clinical protocol to convert patients to belatacept if they had a stable but low GFR and they were at least 1-month posttransplant. Eligible patients had stable but low eGFR usually < 40 mL/min per 1.73 m2. We used direct matching to select 1 control case for each patient converted to belatacept. The primary outcome was the change in eGFR from the point of belatacept conversion to 4 months postconversion (delta eGFR). Results There were 30 patients in the conversion group and 30 in a direct matched control group. The median preconversion eGFR for the entire cohort was 23.0 mL/min per 1.73 m2 with an interquartile range of 15.7 to 31.4. The delta eGFR was 11.0 (12.9) mL/min per 1.73 m2 in belatacept group and 4.8 (10.5) mL/min per 1.73 m2 in the control group (P = 0.045). Acute rejection postconversion occurred in 5 (16.7%) in the conversion group and none of the control group (P = 0.052). Although the delta improvement in eGFR was about 6 mL/min better in the Belatacept group, there was no difference in the slope of inverse creatinine during the 12-month period after conversion between the groups. Conclusions We conclude that early belatacept conversion in kidney transplant recipients with stable low eGFR may only result in a modest increase in GFR.

AB - Background Our aim was to determine the impact of converting from tacrolimus to belatacept in patients with stable low estimated glomerular filtration rate (eGFR) early after kidney transplant. Methods This is a single-center retrospective case control study. During this study period, we had a clinical protocol to convert patients to belatacept if they had a stable but low GFR and they were at least 1-month posttransplant. Eligible patients had stable but low eGFR usually < 40 mL/min per 1.73 m2. We used direct matching to select 1 control case for each patient converted to belatacept. The primary outcome was the change in eGFR from the point of belatacept conversion to 4 months postconversion (delta eGFR). Results There were 30 patients in the conversion group and 30 in a direct matched control group. The median preconversion eGFR for the entire cohort was 23.0 mL/min per 1.73 m2 with an interquartile range of 15.7 to 31.4. The delta eGFR was 11.0 (12.9) mL/min per 1.73 m2 in belatacept group and 4.8 (10.5) mL/min per 1.73 m2 in the control group (P = 0.045). Acute rejection postconversion occurred in 5 (16.7%) in the conversion group and none of the control group (P = 0.052). Although the delta improvement in eGFR was about 6 mL/min better in the Belatacept group, there was no difference in the slope of inverse creatinine during the 12-month period after conversion between the groups. Conclusions We conclude that early belatacept conversion in kidney transplant recipients with stable low eGFR may only result in a modest increase in GFR.

UR - http://www.scopus.com/inward/record.url?scp=85042866833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042866833&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000001985

DO - 10.1097/TP.0000000000001985

M3 - Article

AN - SCOPUS:85042866833

VL - 102

SP - 478

EP - 483

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -